One in Four Oral Semaglutide Users Discontinue Due to GI Side Effects: Database Analysis | Research

The takeaway

Oral semaglutide had a significant discontinuation rate due to adverse effects, predominantly gastrointestinal, with patterns and predictors characterized in a large database analysis.

GI = main barrier
Gastrointestinal side effects are the dominant reason patients stop oral semaglutide, with specific risk factors predicting who will discontinue

What the researchers found

Oral semaglutide: significant AE-related discontinuation predominantly due to GI effects (nausea, vomiting, diarrhea), with patient risk factors identified for predicting discontinuation.

Why it matters

Oral GLP-1 drugs are the future of metabolic medicine, but GI tolerability limits adherence. Understanding discontinuation patterns enables better patient management.

How the study worked

Database analysis of oral semaglutide discontinuation patterns, reasons (AE types), and predictive factors.

What this study cannot tell us

Database study. Cannot capture patients who tolerated side effects. Self-selected population.

How to read the evidence

Database analysis. Real-world tolerability data complementing clinical trial AE reporting.

When this study was published

Published in 2025.

The bigger picture

GI tolerability remains the Achilles heel of GLP-1 drugs, whether injectable or oral. Solving this would dramatically improve real-world effectiveness.

Questions still open

Could slower titration schedules reduce discontinuation?
Would anti-nausea co-medication improve oral semaglutide tolerability?
Are there genetic predictors of GI intolerance?

Common questions

Do many people stop oral semaglutide due to side effects?

A significant proportion discontinue due to GI side effects — mainly nausea, vomiting, and diarrhea. Slow dose titration and taking the pill correctly can help minimize these effects.

How can I reduce nausea from oral semaglutide?

Take it on an empty stomach with a small sip of water, wait 30 minutes before eating, and ensure your doctor titrates the dose slowly. Some patients also benefit from anti-nausea strategies during the titration period.

Read the original research

Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.

Diabetology international, 17(1), 14

View on PubMed ↗Publisher’s paper ↗

Citation

Ishiguro, Mizuki; Nishimura, Rimei. (2026). Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.. Diabetology international, 17(1), 14. https://doi.org/10.1007/s13340-025-00868-0